Physician profile
Christina Chumley
NPI 1043640659
$3,475.09
in general payments reported to CMS, 2019-2025
26 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $307 · 2023: $676 · 2024: $947 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,833.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.86 | 2021-2025 | |
| Amgen INC. | $475.04 | 2021-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $340.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $263.61 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $205.69 | 2021-2025 | |
| Glaxosmithkline, LLC. | $202.64 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $188.28 | 2023-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $186.74 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.28 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.70 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $97.69 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Radius Health, INC. | $78.72 | 2023-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.93 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $75.17 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $36.92 | 2023-2024 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $33.05 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $31.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.42 | 2021 | |
| Sunovion Pharmaceuticals INC. | $27.91 | 2022 | |
| Axsome Therapeutics, INC. | $26.83 | 2023 | Auvelity |
| Cardiva Medical, INC. | $23.03 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Dexcom, INC. | $18.92 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $18.65 | 2021 | |
| Lundbeck LLC | $16.22 | 2025 | Vyepti |
| Insulet Corporation | $14.20 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $13.71 | 2024 | Gardasil, Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Chumley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.